{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.9","value":"51.7"},{"groupId":"OG001","spread":"9.5","value":"49.6"},{"groupId":"OG002","spread":"9.1","value":"49.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"47"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.5","value":"53.5"},{"groupId":"OG001","spread":"9.9","value":"51.3"},{"groupId":"OG002","spread":"4.6","value":"52.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"43"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"title":"Prior to Maintenance Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.6","value":"52.6"},{"groupId":"OG001","spread":"9.4","value":"50.9"},{"groupId":"OG002","spread":"12.7","value":"43.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"43"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"Completion of Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.1","value":"56.2"},{"groupId":"OG001","spread":"10.2","value":"53.9"},{"groupId":"OG002","spread":"13.0","value":"53.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"41"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"title":"12 Months Off Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.6","value":"54.5"},{"groupId":"OG001","spread":"10.1","value":"55.3"},{"groupId":"OG002","spread":"12.6","value":"49.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"title":"24 Months Off Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.3","value":"53.3"},{"groupId":"OG001","spread":"9.8","value":"55.1"},{"groupId":"OG002","spread":"12.2","value":"53.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"33"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"36 Months Off Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.4","value":"56.4"},{"groupId":"OG001","spread":"10.1","value":"55.5"},{"groupId":"OG002","spread":"10.3","value":"55.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"48 Months Off Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.5","value":"51.9"},{"groupId":"OG001","spread":"12.0","value":"57.7"},{"groupId":"OG002","spread":"12.5","value":"58.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"title":"60 Months Off Therapy"}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"86"},{"groupId":"OG002","value":"34"}],"units":"Participants"}],"description":"Scores measuring attention were obtained from the Attention Problems T-score on the BASC-2 instrument which is a parent report. Higher scores indicate more attention problems. The normative mean is 50 with a standard deviation of 10.","dispersionType":"Standard Deviation","groups":[{"description":"Patients with gross total resection (GTR)/no evidence of metastatic (M0) medulloblastoma, nodular desmoplastic or high grade glioma histology will receive induction chemotherapy and low-risk therapy.","id":"OG000","title":"Low-Risk Group"},{"description":"Patients with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease, will receive induction chemotherapy and intermediate-risk therapy.","id":"OG001","title":"Intermediate-Risk Group"},{"description":"Patients with central nervous system (CNS) metastatic disease will receive induction chemotherapy and high-risk therapy.","id":"OG002","title":"High-Risk Group"}],"paramType":"MEAN","populationDescription":"Eligible patients with scores at any of the data collection timepoints were included. Sample sizes differ across timepoints as not all subjects had scores for all timepoints.","reportingStatus":"POSTED","timeFrame":"Baseline, prior to maintenance therapy, completion of therapy, and 12 months, 24 months, 36 months, 48 months, and 60 months off therapy","title":"Neurocognitive Performance Related to Attention as Measured by Attention Problems T-scores","type":"SECONDARY","unitOfMeasure":"score on a scale"}